HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

about

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

Item

http://www.wikidata.org/entity/Q46003410

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@en

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@nl

type

Item

label

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@en

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@nl

prefLabel

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@en

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors.

@nl

P1476

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors

@en

P2093

Iman El-Hariry

http://www.w3.org/2001/XMLSchema#string

Neil Spector

http://www.w3.org/2001/XMLSchema#string

Sarah Bacus

http://www.w3.org/2001/XMLSchema#string

Wenle Xia

http://www.w3.org/2001/XMLSchema#string

Yossi Yarden

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Untangling the ErbB signalling network

P304

205-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1652

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

1868927

http://www.w3.org/2001/XMLSchema#string